CUPERTINO, Calif., Feb. 23, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.
- James E. Brown, President and CEO, will present at the RBC Capital Markets' Global Healthcare Conference on Wednesday, February 29 at 8:00 a.m. Eastern Time. The conference is being held at the New York Palace Hotel in New York City. A live audio webcast of the presentation will be available by accessing http://www.wsw.com/webcast/rbc141/drrx/.
- James E. Brown, President and CEO, will also present at the Cowen and Company 32nd Annual Healthcare Conference on Wednesday, March 7 at 11:20 a.m. Eastern Time. The conference is being held at the Marriott Copley Place in Boston. A live audio webcast of the presentation will be available by accessing http://wsw.com/webcast/cowen6/drrx/.
A live audio webcast of these presentations will also be available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.
NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR®, ELADUR™ and DURIN® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.
Related medicine technology :1
. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results2
. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia3
. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program4
. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call5
. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference6
. DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call7
. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory8
. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results9
. DURECT to Present at the Cowen and Company Healthcare Conference10
. DURECT to Present at the Barclays Capital Global Healthcare Conference11
. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call